Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: Parkinson’s disease (PD) is a common neurodegenerative disease characterized by motor symptoms of tremor, rigidity, bradykinesia, and postural instability. Growing evidence indicates that resveratrol and curcumin they can protect dopaminergic neurons against the neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced cell degeneration. In this article, we formulated and evaluated Intranasal Nanoparticle of Curcumin with resveratrol for treatment of Parkisonism.
Background: Resveratrol and curcumin are polyphenolic compound naturally present in red wine and grapes, has a number of pharmacological effects including anti-inflammation, anti-apoptosis, antioxidation, and others. It is also able to cross the blood-brain barrier and is water soluble but entrance of resveratrol and curcumin into the brain is limited and this work brings a new strategy to overcome these constrains by developing nanosystems capable of protecting resveratrol and curcumin from the extensive degradation and metabolism and enhancing the delivery into the brain in an appropriate therapeutic concentration.
Method: Resveratrol and curcumin loaded chitosan nanoparticles prepared by ionic gelation with tripolyphosphate anions. Nano-particle were characterized for particle size, polydispersity index (PDI), zeta potential, loading capacity, entrapment efficiency in vitro release study, and in vivo distribution after intranasal administration.
Results: The mean particles size, polydispersity index (PDI) and encapsulation efficiency was found to be 144.7 ± 9.45, 0.470 ± 0.07 and 98.56 ± 3.19, respectively. The Nanoparticles showed sustained release profiles for up to 13 h. The concentrations (% Radioactivity/g) in the brain following intranasal administration were found to be significantly higher at all the time points. The concentration of naoparticle was highest in the liver (8.934 ± 0.66), followed by kidneys (5.129 ± 0.34), intestine (3.72 ± 0.23), and lungs (2.207 ± 0.87) in rats following i.n. administration. Gamma scintigraphy imaging in rats was performed to ascertain the localization of drug in the brain.
Conclusion: The results showed significant enhancement of bioavailability in brain, after administration of the Resveratrol and curcumin loaded chitosan nanoparticles which could be a substantial achievement of direct nose to brain targeting in Parkinson’s disease therapy.
To cite this abstract in AMA style:A. Jain, S. Jain. Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/formulations-and-evaluations-of-intranasal-nose-to-brain-delivery-of-curcumin-with-resveratrol-nanoparticle-for-treatment-of-parkisonism/. Accessed December 7, 2023.
« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/formulations-and-evaluations-of-intranasal-nose-to-brain-delivery-of-curcumin-with-resveratrol-nanoparticle-for-treatment-of-parkisonism/